Emcure Pharma (EMCURE)

FairStock Score: 70/100 — STEADY

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look first for quality and price. Emcure Pharma is a ₹36,652 Cr pharma business. It earns 19.57% ROE and 20.72% ROCE, carries Debt/Equity of 0.31, generates ₹756 Cr free cash flow, and scores 8/9 on Piotroski and 4.39 on Altman Z. That points to a sound balance sheet and accounting quality. Promoter holding of 77.87% aligns owners with shareholders. Growth has been impressive: sales up 32.01%, profit up 62.97%, with latest quarter sales ₹2,363 Cr and net profit ₹231 Cr. But five-year revenue CAGR is only 9.36%, so I need proof that recent growth is durable. Valuation is the rub. At ₹1,932.30, P/E is 36.23 and P/B is 7.40. The Graham Number is ₹500.66, giving a margin of safety of -190.72%, meaning this is nowhere near a Graham defensive bargain. EV/EBITDA is 51.68, very rich. Yet DCF intrinsic value is ₹2,133.97 and PEG is 0.50, so if growth persists, the price may not be unreasonable. Dividend yield is only 0.19%, so returns depend on earnings compounding. The figures hint at a competitive advantage via high ROCE, but I cannot quantify the moat from this data. FairStock Score of 70/100 STEADY supports a stalwart classification. The 52-week range is ₹1,306.50-₹2,101.00, so the stock has moved sharply; volatility can create opportunity, but only if price meets value. I’d watch this quality stalwart, but demand a wider margin of safety before buying.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer